Evaluation of Hemostasis in Bleeding and Thrombotic Disorders
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00178594 |
Recruitment Status :
Recruiting
First Posted : September 15, 2005
Last Update Posted : November 23, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Blood Coagulation Disorders, Inherited Thrombotic Disorder |
Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Observational Model: | Other |
Time Perspective: | Prospective |
Official Title: | Evaluation of Hemostasis in Bleeding and Thrombotic Disorders Using the Roteg Analyzer and the Thrombin Generation Assay |
Actual Study Start Date : | October 2002 |
Estimated Primary Completion Date : | January 2022 |
Estimated Study Completion Date : | January 2022 |

- Assess primary and secondary hemostasis in individuals with bleeding and clotting disorders [ Time Frame: 24 hours ]Coagulation will be assessed by continuously recording clot firmness, thrombin generation, and platelet function

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 98 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Congenital or Acquired Bleeding Disorder Congenital or Acquired Thrombotic Disorder
Exclusion Criteria:
- Poor venous access

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00178594
Contact: Madeline Cantini, BSN | 713-500-8377 | madeline.cantini@uth.tmc.edu |
United States, Texas | |
The Univerisity of Texas Health Science Center at Houston | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Madeline Cantini, BSN 713-500-8377 madeline.cantini@uth.tmc.edu | |
Principal Investigator: Miguel Escobar, MD |
Principal Investigator: | Miguel Escobar, M.D. | The University of Texas Health Science Center, Houston |
Responsible Party: | Miguel Escobar, Associate Professor - Gulf States Hemophilia Center, The University of Texas Health Science Center, Houston |
ClinicalTrials.gov Identifier: | NCT00178594 |
Other Study ID Numbers: |
HSC-MS-02-174 |
First Posted: | September 15, 2005 Key Record Dates |
Last Update Posted: | November 23, 2020 |
Last Verified: | November 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | Undecided at this time |
Hereditary Bleeding disorder Thrombotic Disorder |
Hemostatic Disorders Thrombosis Blood Coagulation Disorders Blood Coagulation Disorders, Inherited Disease Hemorrhage Pathologic Processes |
Hematologic Diseases Vascular Diseases Cardiovascular Diseases Hemorrhagic Disorders Genetic Diseases, Inborn Embolism and Thrombosis |